Lanxess (LXS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting opened with acknowledgment of the challenging environment for the European chemical industry, emphasizing the need for proactive internal measures.
Financial performance review
Group sales in 2025 were EUR 5.7 billion, an 11% decline from the previous year.
EBITDA pre exceptionals fell by 17% to EUR 510 million, mainly due to weak demand and divestments.
Net financial debt reduced to around EUR 2 billion, nearly 50% less than in 2022.
Cash reserves at year-end were about EUR 500 million, with undrawn credit lines of EUR 1.4 billion.
Dividend announcements
Proposal for a stable dividend of EUR 0.10 per share, totaling approximately EUR 9 million, signaling continuity and financial restraint.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lanxess
- Sales and EBITDA fell sharply, but full-year guidance is maintained amid persistent market headwinds.LXS
Q1 2026 (Media)12 May 2026 - Sales and EBITDA dropped, but full-year guidance is confirmed and Q2 is set to improve.LXS
Q1 20267 May 2026 - Revenue and earnings declined, but debt reduction and cost cuts support a late 2026 recovery.LXS
Q4 2025 (Media)1 May 2026 - 2026 EBITDA guidance is €450–550 million, with recovery expected in H2 2026.LXS
Q4 202519 Mar 2026 - Earnings rose, costs fell, and sustainability advanced amid global uncertainty and strategic refocus.LXS
AGM 20253 Feb 2026 - Q2 2024 EBITDA pre exceptionals surged 69% year-over-year despite lower sales.LXS
Q2 20241 Feb 2026 - EBITDA pre exceptionals jumped 45% and net income returned to profit in Q3 2024.LXS
Q3 202416 Jan 2026 - EBITDA rose 20% in 2024 as cost savings and portfolio focus drove profitability gains.LXS
Q4 202426 Dec 2025 - Q2 sales and EBITDA fell on weak demand, but net debt dropped after Urethane divestment.LXS
Q2 202523 Nov 2025